4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta
finasteride
CAS: 98319-26-7
Molecular Formula: C23H36N2O2
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Names and Identifiers
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Physico-chemical Properties
| Molecular Formula | C23H36N2O2 |
| Molar Mass | 372.54 |
| Density | 1.065±0.06 g/cm3(Predicted) |
| Melting Point | 253 °C |
| Boling Point | 576.6±50.0 °C(Predicted) |
| Specific Rotation(α) | 405 -59° (c = 1 in methanol) |
| Flash Point | 177.448°C |
| Water Solubility | insoluble |
| Solubility | DMSO: 32mg/mL, soluble |
| Vapor Presure | 0mmHg at 25°C |
| Appearance | solid |
| Color | white to beige |
| Merck | 14,4082 |
| pKa | 14.17±0.70(Predicted) |
| Storage Condition | room temp |
| Refractive Index | 1.524 |
| Physical and Chemical Properties | Water-soluble |
| Use | For the treatment of male prostate hypertrophy and alopecia and other diseases |
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Risk and Safety
| Risk Codes | R22 - Harmful if swallowed R61 - May cause harm to the unborn child R60 - May impair fertility R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S53 - Avoid exposure - obtain special instructions before use. S36 - Wear suitable protective clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S24/25 - Avoid contact with skin and eyes. |
| WGK Germany | 3 |
| RTECS | CL5245000 |
| HS Code | 29379000 |
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Reference
| Reference Show more | 1. Zheng, Ruirong, et al. "Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors." Analytical and bioanalytical chemistry 412.7 (2020): 1685-1692.https: 2. [IF=4.142] Zheng Ruirong et al."Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors."Anal Bioanal Chem. 2020 Mar;412(7):1685-1692 |
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Nature
Open Data Verified Data
white or off-white crystalline solid. Soluble in chloroform, dimethyl sulfoxide, ethanol, methanol or n-propanol, insoluble in propylene glycol or polyethylene glycol 400, very slightly soluble in 0. Imol/L hydrochloric acid, 0. Imol/L sodium hydroxide solution or water. The melting point is about 257 °c; There is a melting point of 252~254 °c.
Last Update：2024-01-02 23:10:35
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Preparation Method
Open Data Verified Data
with pregnenolone as raw material, obtained by multi-step reaction.
Last Update：2022-01-01 09:24:18
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Standard
Authoritative Data Verified Data
This product is n-tert-butyl-3-oxo-4-aza-5a-androst-1-Diluted -17 pieces of formamide. The content of C23H36N202 shall be 98.0% ~ 102.0% calculated as dry product.
Last Update：2024-01-02 23:10:35
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Trait
Authoritative Data Verified Data
- This product is white or off-white crystalline powder; Odorless.
- This product is soluble in methanol and ethanol, slightly soluble in acetonitrile and ethyl acetate, almost insoluble in water; Soluble in glacial acetic acid.
specific rotation
take about 0.5g of this product, accurately weigh it, put it in a 50ml measuring flask, add methanol to dissolve and dilute to the scale, shake well, and determine it according to law (General rule 0621), the specific rotation was 12 ° to 14 °.
Last Update：2022-01-01 13:35:00
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Use
Open Data Verified Data
developed by Merck, Inc., launched in 1992. 4 A azepine steroid, a 5a-proenzyme inhibitor, is effective in reducing dihydrotestosterone in the blood and prostate. Finasteride has no affinity for the androgen receptor. For the treatment of benign prostatic hyperplasia.
Last Update：2022-01-01 09:24:18
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Differential diagnosis
Authoritative Data Verified Data
- take about 20mg of this product, add sodium hydroxide O.lg, place it in a test tube, mix it evenly, heat it to melt, and the generated gas can turn the wet red litmus test paper blue.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 793) (if not, take this product and finasteride reference product, dissolve with methanol respectively, and then evaporate to dryness, the residues were determined according to the law, and the infrared absorption spectra of the two should be consistent).
Last Update：2022-01-01 13:35:00
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Exam
Authoritative Data Verified Data
Related substances
take about 25mg of this product, put it in a 25ml measuring flask, add mobile phase to dissolve and dilute to the scale, shake well, as a test solution; Take 1ml of test solution with precision, set in a 200ml measuring flask, dilute to the scale with the mobile phase, and shake to serve as a control solution. According to the chromatographic conditions under the content determination item, 20 u1 of the test solution and the control solution are accurately measured and injected into the human liquid chromatograph respectively, and the chromatogram is recorded to 2 times of the retention time of the main component chromatographic peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.5% ), the sum of each impurity peak area shall not be greater than 2 times (1.0%) of the main peak area of the control solution. The peaks in the chromatogram of the test solution which were 0.1 times smaller than the main peak area of the control solution were ignored.
residual solvent
- was measured according to the residual solvent measurement method (General 0861 third method).
- chromatographic conditions and system suitability test a capillary column (HP-inowax, l.0 temperature increase, starting temperature 40°C, 6 min, the temperature was increased to 220°C at a rate of 10°C per minute for 2 minutes. The inlet temperature was 22CTC, and the detector temperature was 240°C. Take the reference solution lul and inject it into the gas chromatograph, and the separation degree between the peaks of each component shall meet the requirements.
- preparation of internal standard solution a suitable amount of N-butanol was taken, and N-methylpyrrolidone was added to prepare a solution containing 0.2mg of N-butanol per 1 ml, which was obtained by shaking.
- determination of cyclohexane, Tetrahydrofuran, ethyl acetate, methanol, dichloromethane, toluene, dioxane, pyridine, chlorobenzene, N, N-dimethylformamide and ethylene glycol appropriate amount, precision weighing, add the internal standard solution to make each 1 ml containing cyclohexane 0.194mg, tetrahydrofuran 0.036mg, ethyl acetate 0.25mg, methanol 0.15mg, dichloromethane 0.03mg, toluene 0.044mg, dioxane 0.019mg, pyridine 0. The solution of Olmg, chlorobenzene 0.018mg, N, N-dimethylformamide 0.044mg and ethylene glycol 0.031mg was used as the reference solution. In addition, take about 0.5g of this product, weigh it accurately and put it in a 10ml measuring flask, add internal standard solution to dissolve and dilute to the scale, shake, as a test solution. The sample solution and the reference solution of 1 u1 were respectively injected into the gas chromatograph, and the chromatogram was recorded. Based on the peak area calculated by internal standard method, the residues of cyclohexane, Tetrahydrofuran, ethyl acetate, methanol, dichloromethane, toluene, dioxane, pyridine, chlorobenzene, N ,N-dimethylformamide and ethylene glycol shall meet the requirements.
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
selenium
take this product O.lg, according to the law inspection (General 0804), should comply with the provisions (0.005%).
arsenic salt
take 0.5g of this product, add 0.5g of calcium hydroxide, mix well, heat to carbonization with small fire, Ash at 550°C, add 5ml of hydrochloric acid and 23ml of water, and operate according to law (General rule 0822), the provisions (0.0004%) shall be met.
Last Update：2022-01-01 13:35:01
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with eighteen alkyl silane was used as a filler, acetonitrile-water (50:50) was used as a mobile phase, the detection wavelength was 210nm, and the column temperature was 30°C. An appropriate amount of finasteride and impurity I was taken, and the mobile phase was added to dissolve and dilute to prepare a solution containing 0.1 mg of finasteride and 0.01 mg of impurity per 1 ml as a system applicable solution. 20ul injection liquid chromatograph is taken and the chromatogram is recorded. The number of theoretical plates is not less than 3000 based on finasteride peak. The resolution between finasteride peak and impurity I peak shall meet the requirements.
assay
take about 25mg of this product, weigh it accurately, put it in 25ml measuring flask, add appropriate amount of mobile phase to dissolve and dilute to the scale, shake well, take 5ml accurately, put it in 50ml measuring flask, dilute to the scale with mobile phase, shake well, as the test solution, take 20ul injection liquid chromatograph with precision, record the chromatogram; Take appropriate amount of finasteride reference substance, determine with the same method, according to the external standard method to calculate the peak area, that is.
Last Update：2022-01-01 13:35:02
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Category
Authoritative Data Verified Data
5a-reductase inhibitors.
Last Update：2022-01-01 13:35:02
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 13:35:03
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Finasteride Tablets
Authoritative Data Verified Data
This product contains Finasteride (C23H36N202) should be 95.0% to 105.0% of the label.
trait
This product is white or white-like tablets or film-coated tablets, white or white-like after removing the coating.
identification
- take an appropriate amount of fine powder of this product (about 20mg equivalent to finasteride), add 10ml of methanol, dissolve finasteride by ultrasound, filter, evaporate the filtrate under reduced pressure, and add sodium hydroxide O.lg, mixing, heating, the resulting gas can make the wet red litmus paper blue.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
examination
- Related substances take an appropriate amount of fine powder of this product (about 25mg equivalent to finasteride), put it in a 25ml measuring flask, add an appropriate amount of mobile phase, shake to dissolve finasteride and dilute it to the scale, shake well, filter, the continuous filtrate was taken as the test solution; 1 ml of the test solution was accurately measured, placed in a 200ml measuring flask, diluted to the scale with the mobile phase, and shaken to serve as a control solution. According to the chromatographic conditions under the content determination item, 20 u1 of the test solution and the control solution are accurately measured, and the human liquid chromatograph is injected respectively, and the chromatogram is recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.5% ), the sum of each impurity peak area shall not be greater than 2 times (1.0%) of the main peak area of the control solution. The peaks in the chromatogram of the test solution which were 0.1 times smaller than the main peak area of the control solution were ignored.
- Content uniformity: Take 1 tablet of this product, grind it finely, put it in a 10ml ( lmg specification) or 50ml(5mg specification) measuring flask, and add an appropriate amount of mobile phase, shake to dissolve finasteride and dilute to the scale, shake, filter, take 20 u1 filtrate accurately, measure according to the method under the content determination item, calculate the content of each tablet, the provisions shall be met (General rule 0941).
- dissolution of this product, according to the dissolution and release determination method [General rule 0931 third method (lmg specification) or second method (5mg specification)], water 200ml(lmg specification) or 900ml( 5mg specification) for the dissolution medium, the speed is 50 rpm, according to the law, after 45 minutes, take the solution 10ml, filtration, take the filtrate as the test solution; take finasteride control about 12.5mg, precision weighing, put it in 50ml measuring flask, add a small amount of methanol to dissolve, dilute it with water to scale, shake well, take 2ml, put it in 100ml measuring flask, water was added to dilute to the scale, shake, as a control solution. According to the chromatographic conditions under the content determination item, 50 u1 of each of the test solution and the reference solution are accurately measured and injected into the liquid chromatograph respectively to record the chromatogram, the dissolution amount of each tablet was calculated by the peak area according to the external standard method. The limit is 75% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler, acetonitrile-water (50:50) as mobile phase, the detection wavelength was 210mn, the column temperature was 30°C. Take the appropriate amount of finasteride and impurity I, add the mobile phase to dissolve and dilute to make finasteride 0.lmg with impurities 10.Olmg solution, as the system applicable solution, take 20u1 injection human liquid chromatograph, record chromatogram, the number of theoretical plate according to finasteride peak is not less than 3000, the resolution between the finasteride peak and the impurity I peak should be satisfactory.
- determination of this product 30 tablets (lmg specification) or 20 tablets (5mg specification), Precision weighing, fine grinding, precision weighing fine powder appropriate amount (about 1Omg equivalent to finasteride), add appropriate amount of mobile phase to 100ml measuring flask, shake to dissolve finasteride and dilute to the scale, shake well, filter, and take the continued filtrate as the test solution, A 20ul injection liquid chromatograph was accurately measured and the chromatogram was recorded. Another 10 mg of finasteride control was accurately weighed and placed in a 100ml measuring flask, same method determination. According to the external standard method to calculate the peak area, that is.
category
with finasteride.
specification
(l)lmg (2)5mg
storage
light shielding, sealed storage.
Last Update：2022-01-01 13:35:04
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Finasteride Capsules
Authoritative Data Verified Data
This product contains Finasteride (C23H36N202) should be 95.0% to 105.0% of the label.
trait
The content of this product is white or white particles or powder.
identification
- take an appropriate amount of the contents of this product (about 20mg equivalent to finasteride), add 10ml of methanol, ultrasonic dissolution of finasteride, filtration, vacuum evaporation of filtrate, addition of sodium hydroxide 0.lg, mixing, heating, the resulting gas can turn the moist red litmus paper blue.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
examination
- Related substances take an appropriate amount of the contents of this product (about 25mg equivalent to finasteride), put it in a 25ml measuring flask, add an appropriate amount of mobile phase, shake to dissolve finasteride and dilute it to the scale, shake and filter, the continuous filtrate was taken as the test solution; 1ml of the test solution was accurately measured, placed in a 200ml measuring flask, diluted to the scale with the mobile phase, and shaken to serve as a control solution. According to the chromatographic conditions under the content determination item, 20 u1 of the test solution and the control solution are accurately measured, and the human liquid chromatograph is injected respectively, and the chromatogram is recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.5%), the sum of each impurity peak area shall not be greater than 2 times (1.0%) of the main peak area of the control solution. The peaks in the chromatogram of the test solution which were 0.1 times smaller than the main peak area of the control solution were ignored.
- Content uniformity: Take 1 capsule of this product, pour the content into a 50ml measuring flask, wash the capsule shell with mobile phase, incorporate the washing solution into the measuring flask, and add an appropriate amount of mobile phase, shake to dissolve finasteride and dilute to the scale, shake well, filter, take 20 u1 of continued filtrate with precision, measure according to the method under the content determination item, calculate the content of each particle, the provisions shall be met (General rule 0941).
- the dissolution of this product, according to the dissolution and release determination method (General rule 0931 second method), with water 1000ml as the dissolution medium, the speed is 50 rpm, according to the law, after 45 minutes, take 10ml of the solution, filter, and take the filtrate as the test solution; Take about 12.5mg of finasteride reference substance, weigh it accurately and put it into a 50ml measuring flask, add a small amount of methanol to dissolve, dilute to scale with water, shake well, take 2ml of precision, put in lOOml measuring flask, dilute to scale with water, shake well, as a reference solution. According to the chromatographic conditions under the content determination item, 50 u1 of each of the test solution and the reference solution are accurately measured and injected into the liquid chromatograph respectively to record the chromatogram, according to the external standard method, the dissolution amount of each particle was calculated by the peak area. The limit is 75% of the labeled amount and shall be in accordance with the provisions.
- others should comply with the relevant provisions under the capsule (General 0103).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler, acetonitrile-water (50:50) as mobile phase, the detection wavelength was 210nm, the column temperature was 30°C. Take the appropriate amount of finasteride and impurity I, add the appropriate amount of mobile phase to dissolve and dilute to make finasteride in 1 ml. lmg with impurities 10.Olmg solution, as the system applicable solution, take 20u1 injection of human liquid chromatography, record chromatogram. The number of theoretical plates shall not be less than 3000 calculated by finasteride peak, and the separation degree between finasteride peak and impurity I peak shall meet the requirements ^
- The determination method is to take 20 capsules of this product, accurately weigh and calculate the average loading. Take the content, mix and grind it finely, weigh an appropriate amount of fine powder (about 25mg of finasteride), put it in a 50ml measuring flask, add an appropriate amount of mobile phase, shake to dissolve finasteride and dilute it to the scale, shake well, filter, take 10ml filtrate accurately, put it in 50ml measuring flask, dilute it with mobile phase to scale, shake well, use it as test solution, take human liquid chromatograph accurately, the chromatogram was recorded, and finasteride reference substance was measured by the same method, about 25mg. According to the external standard method to calculate the peak area, that is.
category
with finasteride.
specification
5mg
storage
light shielding, sealed storage.
Last Update：2022-01-01 13:35:05
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta - Reference Information
| EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
| treatment of benign prostatic hyperplasia | Finasteride is a basic drug for the treatment of benign prostatic hyperplasia and prostatitis in China, it is a synthetic 4-nitrogen steroid hormone compound, belongs to the anti-sex hormone drugs, can selectively inhibit the 5 alpha-reductase, so that the conversion of testosterone into 5 alpha-dihydrotestosterone (DHT) process resistance, the level of androgen in prostate cells decreases, the prostate specific antigen in serum decreases, the volume of enlarged prostate decreases, and the urine flow rate increases, so as to alleviate the symptoms of patients and achieve the purpose of treating prostatic hyperplasia. The drug is characterized by its ability to selectively block the stimulating effect of androgens on the prostate, but rarely affects the sexual function of men. prostate hyperplasia, also known as prostatic hypertrophy, causes compression of the neck of the bladder and the posterior urethra, urinary tract obstruction and other symptoms and complications, causing patients to feel deeply painful, more than 50 years old male population. |
| drug for the treatment of male pattern hair loss | finasteride is also a specific inhibitor of 5-alpha-reductase, which belongs to resistance hormone drugs, it prevents the conversion of testosterone to dihydrotestosterone, thereby reducing the synthesis of dihydrotestosterone, reducing the content of dihydrotestosterone in the scalp hair follicles and serum, and restoring the function of the hair follicle papillae that have been inhibited, to promote hair growth and prevent continued hair loss, finasteride is currently the only FDA-approved oral drug for the treatment of male pattern hair loss, the recommended dose of 1mg. |
| Use | 5 α-reductase inhibitor, inhibits the conversion of testosterone to dihydrotestosterone. For the treatment of benign prostatic hyperplasia. for the treatment of male prostate hypertrophy and alopecia and other diseases |
| production method | pregnenolone as raw material. First, it reacts with pyridine and then reacts with sodium methoxide to give 3-hydroxy-5-androstene-17 β-carboxylic acid methyl ester (III). Then, the mixture was refluxed with aluminum isopropoxide in toluene and cyclohexanone. Filtration, washing, drying and concentration under reduced pressure. Petroleum ether was added, stirred at 5 ° C., and the oxidation product (IV) was obtained by Suction filtration. The yield was 74.6%. The oxidation product and 95% ethanol and 10% potassium hydroxide solution were refluxed under nitrogen. After ethanol was distilled off under reduced pressure, the pH was adjusted to about 3 with 6mol of several hydrochloric acids. Suction filtration, the filter cake is washed with water to neutral, dried to obtain hydrolysis product (V), yield 96.4%. The hydrolysate was dissolved in tert-butyl alcohol, and an aqueous solution of anhydrous sodium carbonate was added under stirring. Under reflux, an aqueous solution of Sodium periodate and potassium permanganate was added dropwise, and reflux was added. Cooling, filtration. After the filtrate was distilled off of most of the tert-butanol under reduced pressure, the pH was adjusted to about 2 with 6mol/L hydrochloric acid under ice bath. The extract was extracted with ethyl acetate, washed with saturated sodium chloride and dried. Evaporated to dryness under reduced pressure, Recrystallization from ethyl acetate gave the ring-opened product (VI) in 66% Yield. Ammonia gas was introduced into the ethylene glycol under cooling in an ice bath, and the ring-opened product was added and reacted slowly up to 180 °c. Cooling, water was added, with 6mol/I. Hydrochloric acid was adjusted to a pH of about 2. The solid was collected by filtration, washed with water until neutral, and recrystallized from dimethylformamide to obtain a cyclization product (VII) in 62.1% yield. The cyclization product, together with platinum dioxide, acetic acid and a small amount of perchloric acid, was hydrogenated at 85 °c and atmospheric pressure. After the catalyst was filtered off, it was concentrated to dryness under reduced pressure. The residue was recrystallized from dimethylformamide to give a hydrogenated product (VIII) in a yield of 92.9%. The hydrogenated product was mixed with triphenylphosphine, toluene and 2,2 '-bipyridine disulfide (DPDS) and stirred at room temperature. Pyridine sulfide (IX) was separated by column chromatography with a yield of 79.0%. The sulfide and anhydrous tetrahydrofuran and tert-butylamine were stirred overnight at room temperature, dichloromethane was added, washed with 2mol/L hydrochloric acid and saturated sodium chloride, and dried, Concentration under reduced pressure. The residue was recrystallized from ethyl acetate to obtain the amide product (X) in 77.1% yield. The amide, together with benzeneselenite and chlorobenzene, is refluxed and the solvent and water formed are slowly distilled off. The crude product was separated by column chromatography and recrystallized from ethyl acetate to obtain White finasteride crystals with a yield of 52.3% and a melting point of 253-255 ℃. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 20:52:54
Supplier List
Featured Products
Product Name: FINASTERIDE Request for quotationCAS: 98319-26-7
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Product Name: finasteride Request for quotation
CAS: 98319-26-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 98319-26-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Finasteride Visit Supplier Webpage Request for quotationCAS: 98319-26-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Featured Products
Product Name: FINASTERIDE Request for quotationCAS: 98319-26-7
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Product Name: finasteride Request for quotation
CAS: 98319-26-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 98319-26-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Finasteride Visit Supplier Webpage Request for quotationCAS: 98319-26-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History